Synthesis of a Novel Boronic Acid Transition State Inhibitor, MB076: A Heterocyclic Triazole Effectively Inhibits <i>Acinetobacter</i>-Derived Cephalosporinase Variants with an Expanded-Substrate Spectrum
R.A. Powers, Cynthia M. June, Micah C. Fernando, Erin R. Fish, Olivia L. Maurer, R. Baumann, Trevor J. Beardsley, Magdalena A. Taracila, Susan D. Rudin, Kristine M. Hujer, Andrea M. Hujer, Nicolò Santi, Valentina Villamil, Maria Luisa Introvigne, Fabio Prati, Emilia Caselli, Robert A. Bonomo, Bradley J. Wallar
Abstract
High Resolution Image Download MS PowerPoint Slide Class C Acinetobacter -derived cephalosporinases (ADCs) represent an important target for inhibition in the multidrug-resistant pathogen Acinetobacter baumannii . Many ADC variants have emerged, and characterization of their structural and functional differences is essential. Equally as important is the development of compounds that inhibit all prevalent ADCs despite these differences. The boronic acid transition state inhibitor, MB076, a novel heterocyclic triazole with improved plasma stability, was synthesized and inhibits seven different ADC β-lactamase variants with K i values <1 μM. MB076 acted synergistically in combination with multiple cephalosporins to restore susceptibility. ADC variants containing an alanine duplication in the Ω-loop, specifically ADC-33, exhibited increased activity for larger cephalosporins, such as ceftazidime, cefiderocol, and ceftolozane. X-ray crystal structures of ADC variants in this study provide a structural context for substrate profile differences and show that the inhibitor adopts a similar conformation in all ADC variants, despite small changes near their active sites.